公开(公告)号：EP1432429A1

公开(公告)日：2004-06-30

申请号：EP02775733.5

申请日：2002-08-30

申请人： Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： WOLTERING, Eugene, A. ,  HORNICK, Conrad, A. ,  MYERS, Amy, E.

IPC分类号： A61K35/78

CPC分类号： C08B37/006 ,  A23L2/02 ,  A23L33/105 ,  A61K36/746 ,  Y02A50/401

摘要： Noni juice and a protein-free, alcohol precipitate of Noni juice inhibited angiogenesis in in vitro human angiogenesis models. When growth medium contained Noni juice at least over the range from about 2.5% to about 33% (by volume), angiogenesis was blocked. Moreover, Noni juice and an ethanol precipitate were able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Noni juice was effective in inhibiting the growth of angiogenic vessels from breast cancer explants. It will also be effective in treating cancers and non-cancerous diseases whose response includes an increase in angiogenesis, e.g., retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, and psoriasis. The primary antiangiogenic component is believed to be a carbohydrate with a molecular weight less than about 6000 Daltons. In an initial experiment, oral administration of Noni juice appeared to adversely affect the antioangiogenic component(s) in the juice.

公开(公告)号：EP1553938B1

公开(公告)日：2007-01-03

申请号：EP03748446.6

申请日：2003-10-13

申请人： BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

发明人： WOLTERING, Eugene, A.

IPC分类号： A61K31/427 ,  A61P5/00 ,  A61P5/18 ,  A61P35/00

CPC分类号： A61K31/427

摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having hyperparathyroidism comprising administering to said animal a therapeutically effective amount of an epothilone derivative of formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP0961591A1

公开(公告)日：1999-12-08

申请号：EP98966733.0

申请日：1998-11-23

申请人： Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： WOLTERING, Eugene, A. ,  ESPENAN, Gregory, D.

IPC分类号： A61B19 ,  A61K51

CPC分类号： A61K51/121

摘要： Administration of a radioisotopic compound by infusion over a period of time greater than two hours, preferably greater than twelve hours, greatly increases the maximum radioactivity that accumulates in the target cell. The efficacy of the administration of the radiolabeled compound can be increased about five times higher than prior bolus injection or short infusion methods. This method enhances the tumor to background ratio by increasing the actual radioligand accumulated inside the tumor cells. This technique works for any radiolabeled compound whose cellular uptake is limited by a cellular process of either binding to a cellular receptor or to a transport protein. Once the radiolabeled compound is bound and internalized, the ability of an unlabeled compound to compete with the radioligand is markedly decreased. The primary factor governing residence time after internalization is the physical half-life of the radioisotope, not biologic half-life.

公开(公告)号：EP0961591B1

公开(公告)日：2008-05-14

申请号：EP98966733.2

申请日：1998-11-23

申请人： BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

发明人： WOLTERING, Eugene, A. ,  ESPENAN, Gregory, D.

IPC分类号： A61B19/00 ,  A61K51/12 ,  A61P35/00

CPC分类号： A61K51/121

摘要： Administration of a radioisotopic compound by infusion over a period of time greater than two hours, preferably greater than twelve hours, greatly increases the maximum radioactivity that accumulates in the target cell. The efficacy of the administration of the radiolabeled compound can be increased about five times higher than prior bolus injection or short infusion methods. This method enhances the tumor to background ratio by increasing the actual radioligand accumulated inside the tumor cells. This technique works for any radiolabeled compound whose cellular uptake is limited by a cellular process of either binding to a cellular receptor or to a transport protein. Once the radiolabeled compound is bound and internalized, the ability of an unlabeled compound to compete with the radioligand is markedly decreased. The primary factor governing residence time after internalization is the physical half-life of the radioisotope, not biologic half-life.

公开(公告)号：EP1553938A1

公开(公告)日：2005-07-20

申请号：EP03748446.6

申请日：2003-10-13

申请人： BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

发明人： WOLTERING, Eugene, A.

IPC分类号： A61K31/427 ,  A61P5/00 ,  A61P5/18 ,  A61P35/00

CPC分类号： A61K31/427

摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having hyperparathyroidism comprising administering to said animal a therapeutically effective amount of an epothilone derivative of formula (I) or a pharmaceutically acceptable salt thereof.